Results 231 to 240 of about 29,202 (297)

Is Dysphagia in Multiple System Atrophy Responsive to Levodopa? Results from a Retrospective Study

open access: yesMovement Disorders Clinical Practice, Volume 13, Issue 3, Page 683-691, March 2026.
Abstract Background Dysphagia remains a major clinical concern in multiple system atrophy (MSA), and so far, lacks relevant treatment options. Objective To systematically assess levodopa‐responsiveness of dysphagia in MSA. Methods 19 MSA‐patients underwent endoscopic swallowing evaluation in Off‐ and On‐state, following an adapted FEES‐levodopa‐test ...
Florin Gandor   +10 more
wiley   +1 more source

Impact of Schizophrenia Spectrum Disorders on the Receipt of Invasive and Systemic Therapy for Colorectal Cancer: A Nationwide Multicenter Retrospective Cohort Study in Japan

open access: yesActa Psychiatrica Scandinavica, Volume 153, Issue 3, Page 191-199, March 2026.
ABSTRACT Introduction This study examined treatment disparities for colorectal cancer among patients diagnosed with schizophrenia spectrum disorders (SSD), focusing on invasive treatments and stage‐appropriate systemic therapy within a universal healthcare system.
Masaki Fujiwara   +12 more
wiley   +1 more source

High Risk of Colorectal Cancer After High‐Grade Dysplasia in Inflammatory Bowel Disease Patients

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 5, Page 706-714, March 2026.
The advantages of colon‐sparing treatment for high‐grade dysplasia should be weighed against the higher risk of metachronous colorectal cancer and the subsequent need for stringent endoscopic surveillance. ABSTRACT Background There are limited data on colorectal cancer (CRC) risk after high‐grade dysplasia in inflammatory bowel disease.
Monica E. W. Derks   +4 more
wiley   +1 more source

Efficacy and Recovery of Remimazolam Versus Midazolam in Sedated Colonoscopy: A Multicenter Randomized Controlled Trial in Japan

open access: yesDigestive Endoscopy, Volume 38, Issue 3, March 2026.
ABSTRACT Objectives Sedation during colonoscopy is becoming increasingly important. Remimazolam, an ultra‐short‐acting benzodiazepine, has a shorter pharmacokinetic half‐life than that of midazolam. This study examined whether remimazolam provides superior sedation during colonoscopy in Japanese patients.
Daisuke Yamaguchi   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy